Illumina Inc. and Roche Holding AG entered into a 15-year collaboration agreement to develop cancer testing technology that uses gene sequencing.
Under the agreement, Illumina will grant Roche rights to develop and distribute diagnostic tests that use Illumina's NextSeq 550Dx system as well as any future gene sequencing systems.
Roche will assist with new companion diagnostic claims to complement Illumina's TruSight Oncology 500 assay that is used for profiling tumor samples. Companion diagnostics are medical devices that help physicians determine whether the benefits of a particular therapy outweigh its risks.
As part of the agreement, Roche will develop Avenio in-vitro diagnostic tests, and Illumina will continue to market the sequencing system along with consumables.
In addition, both companies will collaborate to develop tests and diagnostic claims on Trusight Oncology 500 for their cancer pipelines. San Diego-based Illumina will be in charge of the development and regulatory approval process, while Roche will support the development of claims and regulatory filings.
The companies did not disclose the financial terms of the deal.